

Frederick E. Munschauer, III, MD

Irvin and Rosemary Smith Professor and Chair, Department of Neurology
State University of New York at Buffalo School of Medicine & Biomedical Sciences
Chief, The Jacobs Neurological Institute

Dr. Munschauer is a board-certified specialist in neurology and internal medicine with a subspecialty in critical care. He is the Irvin & Rosemary Smith Professor and Chair, Department of Neurology, of the State University of New York at Buffalo School of Medicine and Biomedical Sciences, and he is Chief of The Jacobs Neurological Institute of Kaleida Health, Buffalo, New York.

Dr. Munschauer received his medical degree from McGill University, Montreal, Quebec, Canada, and completed an Internship and Residency in Internal Medicine and a Residency in Neurology at The Johns Hopkins Hospital, Maryland, USA. He also completed a Fellowship in Neurological and Neurosurgical Intensive Care at The National Hospital for Nervous Disease, London, UK. Dr. Munschauer is a member of the American Academy of Neurology, the American Medical Association, the American Society of Neuroimaging, and the Society of Critical Care Medicine. He is currently a member of the National Board of Directors for the National MS Society, as well as serving on their Medical Advisory Board. Additionally, he serves on the Executive Committee of the Consortium of Multiple Sclerosis Centers.

Dr. Munschauer has researched extensively in the use of interferon-b1a (IFN-b1a) as treatment for relapsing-remitting multiple sclerosis (MS) and was coinvestigator of phase III clinical trials and the CHAMPS study. He is also interested in outcomes research in MS. His publications include the phase III clinical trial results, as well as the rationale for early treatment of MS with IFN-b1a, and managing side effects of IFN-b1a in patients. Dr. Munschauer lectures nationally and internationally on the use of IFN-b1a in patients with MS, and is considered one of the leaders in the field of MS treatment.